Remdesivir (GS-5734): Antiviral Nucleoside Analogue for RNA-Dependent RNA Polymerase Inhibition

Executive Summary. Remdesivir (GS-5734) is a monophosphoramidate prodrug that inhibits viral RNA-dependent RNA polymerase (RdRp) by causing premature termination of viral RNA synthesis [APExBIO]. It shows EC₅₀ values as low as 0.03 μM against coronaviruses in cell models, with minimal cytotoxicity within effective ranges [DOI]. In vivo, it suppresses Ebola virus replication and protects rhesus monkeys from lethal outcomes when administered at 10 mg/kg intravenously for 12 days [APExBIO]. Remdesivir targets highly conserved RdRp domains, validated by high-resolution structural studies [DOI]. It is insoluble in water but highly soluble in DMSO (≥51.4 mg/mL), facilitating workflow integration in virology research [APExBIO].

Biological Rationale

Remdesivir (GS-5734) is designed as a broad-spectrum antiviral nucleoside analogue. It targets viral RNA-dependent RNA polymerase (RdRp), a universally conserved enzyme essential for the replication of most RNA viruses, including coronaviruses (SARS-CoV, MERS-CoV) and filoviruses (Ebola virus). The viral RdRp catalyzes the synthesis of new RNA genomes and viral mRNAs, processes that are absent in host cells. Remdesivir exploits the structural and mechanistic conservation of the RdRp active site across diverse RNA viruses, as confirmed in recent high-resolution polymerase complex structures (Grimes et al., 2024). Its prodrug design enables efficient intracellular delivery and conversion to the active triphosphate form. By targeting an enzymatic bottleneck in the viral life cycle, Remdesivir provides a rational, mechanism-based approach for suppressing viral replication.

Mechanism of Action of Remdesivir (GS-5734)

Remdesivir is a monophosphoramidate prodrug of the C-adenosine nucleoside analogue GS-441524. Upon cellular uptake, it is metabolized to its active nucleoside triphosphate form. The active metabolite competes with ATP for incorporation into nascent viral RNA strands by the viral RdRp. Once incorporated, Remdesivir's analogue causes delayed chain termination, stalling further elongation of the viral RNA. This premature termination results from steric hindrance and altered sugar-phosphate backbone geometry [APExBIO]. Recent structures of viral polymerase complexes (including Nipah, Ebola, and coronaviruses) reveal conserved RdRp domains responsible for nucleotide addition and proofreading exoribonuclease activity (Grimes et al., 2024). Remdesivir's efficacy is partly due to its ability to evade the viral exoribonuclease, thus maintaining its chain-terminating effects.

Evidence & Benchmarks

• Remdesivir exhibits potent inhibition of murine hepatitis virus (MHV) with an EC₅₀ of 0.03 μM in infected delayed brain tumor (DBT) cells (Grimes et al., 2024).
• In primary human airway epithelial (HAE) cultures infected with SARS-CoV, Remdesivir displays an EC₅₀ of approximately 0.074 μM (Grimes et al., 2024).
• In vivo, intravenous administration of Remdesivir at 10 mg/kg/day for 12 days significantly reduces Ebola virus titers and protects rhesus monkeys from lethal disease, even with post-exposure treatment [APExBIO].
• Remdesivir demonstrates minimal cytotoxicity in cell-based assays at concentrations well above its antiviral EC₅₀ values [APExBIO].
• Structural studies reveal Remdesivir targets the highly conserved RdRp active site, a validated broad-spectrum antiviral target (Grimes et al., 2024).

This article offers a structured, evidence-based update, extending the detailed mechanistic insights found in "Remdesivir (GS-5734): Mechanistic Insights and Strategic..." by providing explicit benchmarks and structural context for current and prospective antiviral workflows.

For a systems-biology perspective and emerging comparative insights, see "Remdesivir (GS-5734): Expanding the Frontiers of Antivira...", which is complemented here by granular, EC₅₀ data and workflow parameters.

Applications, Limits & Misconceptions

Remdesivir (GS-5734) is used in preclinical and translational research to investigate the inhibition of RNA-dependent RNA polymerase in a range of RNA viruses, including coronaviruses, filoviruses, and paramyxoviruses. Its high selectivity and low cytotoxicity profile make it suitable for cell-based and animal model studies. The compound’s broad-spectrum mechanism allows comparative studies across viral genera, including emerging threats such as Nipah virus, where the RdRp structure is highly conserved (Grimes et al., 2024).

Common Pitfalls or Misconceptions

• Remdesivir is not a cure for viral infections in humans; its use is restricted to scientific research and not approved for diagnostic or therapeutic purposes [APExBIO].
• Remdesivir’s efficacy may be reduced in viruses possessing highly efficient proofreading exoribonuclease activity that can excise incorporated nucleoside analogues (Grimes et al., 2024).
• The compound is insoluble in water and ethanol, requiring dissolution in DMSO for in vitro assays [APExBIO].
• Results derived from non-human primate models may not directly translate to human clinical outcomes.
• Remdesivir is unstable at room temperature and should be stored at -20°C to maintain integrity [APExBIO].

Workflow Integration & Parameters

Remdesivir (GS-5734) from APExBIO (B8398) is supplied as a research-grade compound, recommended for cell culture and animal model studies. It is insoluble in water and ethanol but dissolves to ≥51.4 mg/mL in DMSO. Optimal storage is at -20°C. The molecular weight is 602.58 Da, and the chemical formula is C₂₇H₃₅N₆O₈P. In cell-based assays, concentrations between 0.01–10 μM are typical for dose-response and cytotoxicity evaluation. For in vivo studies, a 10 mg/kg/day intravenous regimen for up to 12 days has been validated in nonhuman primate models. For detailed experimental guidance, see "Remdesivir (GS-5734): Applied Workflows for Antiviral Res...", which this article updates with current EC₅₀ and solubility parameters.

Conclusion & Outlook

Remdesivir (GS-5734) remains a leading research tool for mechanistic studies of viral RNA-dependent RNA polymerase inhibition. Its robust cell and animal model efficacy, low cytotoxicity, and validated mechanism underpin its widespread adoption in coronavirus, Ebola, and emerging virus research. By exploiting conserved polymerase structures and targeting viral replication bottlenecks, Remdesivir provides a rational basis for comparative and translational virology. Future structural studies and resistance surveillance will be crucial for maintaining its research relevance as new viral threats emerge (Grimes et al., 2024).

For specifications, protocols, and ordering, visit the Remdesivir (GS-5734) product page at APExBIO.